A student innovation and entrepreneurship team from SCMU has developed the PM3000 series blood drug concentration analyzer, contributing to China’s precision medicine strategy. This project recently won the gold award in the 2024 China International College Students’ Innovation Competition for Hubei Province.

The PM3000 analyzer employs pioneering two-dimensional liquid chromatography, online solid-phase extraction, and valve-switching technologies. These innovations enable highly accurate analysis of drug concentrations in patients’ blood, providing a scientific basis for personalized medication regimens and reducing drug side effects. Key features of the PM3000 include: enhanced analysis of trace components in complex biological sample, automated blood sample pre-treatment, broader range of blood drug concentration analysis, detection precision at the nanogram level, rapid results within 10 minutes, and efficient multi-sample analysis.

Team leader Liu Wenxiu explaining the instrument’s use.

Photo provided by the School of Innovation and Entrepreneurship

Team members operating the instrument.

Photo provided by the School of Innovation and Entrepreneurship

Zhang Xianglin, Chief Pharmacist at China-Japan Friendship Hospital, highly commended the PM3000’s innovative development, stating it could break the market monopoly of high-end foreign medical devices and promote the autonomous and sustainable development of China’s medical equipment industry.

The startup, Parmacon, aims to build a precision medical device industry chain. Team leader Liu Wenxiu, a pharmacy graduate from SCMU, founded Parmacon in 2019 under the guidance of Professor Li Xiaokuan, an expert in chromatography applications. The team has conducted extensive field research in hospitals to address clinical pain points. Compared to similar products, Parmacon’s two-dimensional liquid chromatograph boasts processing speeds nearly four times faster and a detection accuracy error of less than 2%. The company has obtained 9 invention patents and filed 8 software copyrights. It has also established deep cooperation with the China Instrument and Control Society on rapid blood drug concentration detection methods.

Parmacon’s medical blood drug concentration analyzer has successfully applied for national medical device registration. To date, the company has partnered with 19 hospitals, and its devices have been installed in over 30 hospital units. “Moving forward, we will continue to strengthen industry-academia-research collaboration, engaging deeply with universities, national disease control centers, technology companies, and hospitals to truly serve the industry and contribute innovative strength to the national precision medicine strategy”, said Liu Wenxiu.